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Abstract: This paper aims to analyze the ethical challenges in experimental drug use during the
early stage of the COVID-19 pandemic, using Germany as a case study. In Germany uniform ethical
guidelines were available early on nationwide, which was considered as desirable by other states
to reduce uncertainties and convey a message of unity. The purpose of this ethical analysis is to
assist the preparation of future guidelines on the use of medicines during public health emergencies.
The use of hydroxychloroquine, remdesivir and COVID-19 convalescent plasma in clinical settings
was analyzed from the perspective of the ethical principles of beneficence, non-maleficence, justice
and autonomy. We observed that drug safety and drug distribution during the pandemic affects
all four ethical principles. We therefore recommend to establish ethical guidelines (i) to discuss
experimental treatment options with patients from all population groups who are in urgent need,
(ii) to facilitate the recording of patient reactions to drugs in off-label use, (iii) to expand inclusion
criteria for clinical studies to avoid missing potentially negative effects on excluded groups, and (iv)
to maintain sufficient access to repurposed drugs for patients with prior conditions.
Keywords: SARS-CoV-2; clinical ethics; pharmaceutical preparations; public health; epidemic;
disease outbreak
1. Introduction
The COVID-19 pandemic (Coronavirus disease 2019) has brought discussions on
medical ethics to the foreground. In the last decades, medical ethics was mostly advanced
on a theoretical basis in Germany, without the expectation of needing to provide immediate
guidelines to urgent public health matters. From the first weeks in which the COVID-19
outbreak developed into a pandemic, medical ethics needed to suddenly make a substan-
tial contribution to solving questions of fair distribution of limited medical goods such
as protective equipment, intensive care beds and ventilators [1,2]. Moreover, in Germany,
ethicists responded quickly with a series of recommendations. Noteworthy examples are
the recommendations for regulating access to the COVID-19 vaccine with the participation
of the German Ethics Council [3] and the advisory role of the Working Group of Medical
Ethics Commissions in Germany on clinical research in the pandemic [4]. The Competence
Network Public Health on COVID-19 has provided numerous position papers on the
public health ethics dimensions of health policy decisions, including work on the ethical
dimension of uncertainty [5] and tracing apps [6]. In relation to biomedical research with
human subjects, the PRECOPE projects offers assistance in meeting the World Health
Organization requirements for the transfer of existing ethical standards to the most im-
portant ethical research challenges on COVID-19 [7]. However, neither specialist societies
nor relevant guidelines deal in detail with ethical questions relating the use of potential
COVID-19 therapeutics during the pandemic. Since hydroxychloroquine and remdesivir
have received the greatest attention during the initial phase of the pandemic, we focus
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on these two drugs in our article. In addition, we also include COVID-19 convalescent
plasma as a third therapeutic approach to the two antiviral therapies. These three treatment
options are already studied well enough to carry out a preliminary ethical analysis on
experimental drug use during the pandemic.
The aim of our ethical analysis is to identify on the basis of these three early treatment
options the potential ethical challenges in the use of experimental drugs during the first
phase of the COVID-19 pandemic. For this purpose, central themes were identified in a
thematic analysis of publications in scientific journals, ethics working groups and gov-
ernmental institutions. These publications are analyzed using the four ethical principles
according to Beauchamp and Childress [8]. Our main findings are discussed in relation
to German health regulatory decisions. Germany was selected because ethics groups pro-
vided early on ethical guidelines, the work between ethics groups and public institutions
was generally perceived as constructive, and the relevant publications were well received.
Although it is unclear what impact ethical guidelines actually had on clinical practice,
Germany managed to overcome the first COVID-19 wave with one of the lowest mortality
rates in the region [9], which makes it an important case to explore. The knowledge gained
on ethical challenges can help to prepare for comparable public health emergencies in
the future.
2. Materials and Methods
In our ethical analysis, we began with a literature search to identify the main themes
that require an ethical evaluation. As a first step, a systematic literature search was carried
out on PubMed, Embase and Cochrane Library (including results from 1 January 2020 until
22 October 2020). The search terms included “COVID-19”, “ethics” and “drug use”. The
purpose was to identify publications that address ethical aspects of drug use during the
first ten months of the COVID-19 pandemic. Relevant publications were selected from
the search results obtained after reviewing the titles and abstracts. The decisive factor
for inclusion was the use of hydroxychloroquine, remdesivir or COVID-19 convalescent
plasma to treat patients suffering from COVID-19 symptoms. Publications dealing with
general ethical issues related to off-label use or compassionate use [10] during the COVID-
19 pandemic were also included. Publications on studies that tracked the prophylactic
administration of one of these drugs to study participants without SARS-CoV-2 infection
were excluded. In a second step, we carried out a thematic analysis [11] of all included
publications. We looked for relevant initial themes that touched on at least one of the
four principles according to Beauchamp and Childress (respect for the patient’s autonomy,
non-maleficence, beneficence and justice) [8]. The principles did not have to be named
explicitly. If, for example, the exclusion of HIV-infected people from clinical studies was
mentioned, this was viewed as significant due to the principle of respect for the patient’s
autonomy. As a third step, by combining recurring initial themes and sub-themes, we
inductively generated two main themes. We related the themes to the four ethical principles
to reach new findings and draft our recommendations. Beauchamp and Childress’s four-
principles-approach focuses primarily on individual cases and was not conceived for issues
of collective well-being. However, particularly in the context of justice, the authors also
refer to national and global health policy and the right to health care [8]. Furthermore,
much of the off-label use focusses on individual patients, and in some cases, physicians
assume substantial risks to save with unproven methods their patients. In our analysis,
each of the four principles could be interpreted, and conflicts with the four principles were
identified. A complete moral picture could be gathered.
3. Results of the Ethical Analysis
The literature search with the terms “COVID-19”, “ethics” and “drug use” led to
n = 148 results (122 PubMed, 10 Embase, 16 Cochrane Library) for the first ten months
of the year 2020. After removing duplications and publications in languages other than
German or English, we were left with n = 140 publications. Based on the title or abstract,
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n = 88 results were excluded because they had drugs other than hydroxychloroquine,
remdesivir or COVID-19 convalescent plasma as a central topic. N = 52 publications were
searched for ethical themes. In these publications, we identified 19 initial themes, which
we summarized into five relevant sub-themes:
1. Existing data on pharmacological treatment;
2. Drug research;
3. Treatment outside of clinical trials;
4. Non-medical influences on drug use (e.g., political or economic interests);
5. Distribution of limited medicinal products (including plasma).
We combined the sub-themes 1 to 4 to form the theme “drug safety”. As the sec-
ond main theme, we identified “drug distribution” (Figure 1). We related the identified
ethical challenges to one or more of the four ethical principles according to Beauchamp
and Childress.
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Since COVID-19 is a new disease, and SARS-CoV-2 (Severe Acute Respiratory Syn-
drome Coronavirus 2) is a new pathogen, there were no approved and therefore tested
drugs at the beginning of the pandemic. Several drugs that had already been approved
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for other diseases were evaluated. In addition, so-called sleeping candidates were tested.
These are drugs that have been abandoned during the development process because they
have proven to be insufficiently effective for the originally intended medical application
or have unwanted side effects [12]. Drugs were used experimentally and were gradually
granted drug approval, deviating from standard procedure. The drug approval process
and the legal nature of drug use varies internationally (Box 1). For example, hydroxychloro-
quine, remdesivir and COVID-19 convalescent plasma had an emergency use authorization
in the United States [13–15]. In other countries, these drugs have been given off-label uses
or compassionate uses. Furthermore, from a legal perspective, terms such as emergency
use, off-label use or compassionate use do not mean exactly the same thing in all countries.
Box 1. Glossary of the main legal categories permitting the use of COVID-19 drugs.
Regular marketing European Union: The marketing authorization procedure evaluates whether a medicinal
product is efficacious and safe and whether it has the required pharmaceutical quality [16].
United States: FDA approval of a drug indicates that data on the drug’s effects have been
reviewed and that the drug is determined to provide benefits that outweigh its known and
potential risks for the intended patient group [17].
Emergency use European Union: EU member states can temporarily allow the marketing of an
unauthorized medicinal product in emergency situations. Member states can decide that the
requirements are less stringent than for a conditional marketing authorization [18].
United States: The FDA may authorize unapproved medical products or unapproved uses




This type of authorization is valid for one year and is awarded after an initial validation
showing greater benefits than risks, on the condition that the new data is submitted as it
becomes available [18].
Off-label use This is the use of an approved drug for purposes for which it had not originally received
regulatory approval [20].
Compassionate use European Union: Compassionate use is the use of an unapproved drug that is given to a
group of patients who have a disease that would result in severe disability or is
life-threatening and cannot be satisfactorily treated with an approved drug [10].
United States: Also called “expanded access”. It is an option for patients to get access to
experimental drugs to treat life-threatening or serious health issues outside clinical trials
when no satisfactory alternative treatment options are available [21].
Necessity as a justification for use In German law § 34 StGB is often used to exculpate physicians who attempt to save lives
through non-approved methods, including non-approved drugs, as long as they are
reasonable to avert danger [22].
3.1. Principle of Beneficence
The principle of beneficence demands from the practitioner to promote the well-being
of the patient [8]. A connection to the principle of beneficence could be found for four of
our five identified sub-themes: existing data on pharmacological treatment, drug research,
treatment outside of clinical trials, and distribution of limited medicinal products (including
plasma). Indications that the use of chloroquine, or hydroxychloroquine, can have potential
benefits in COVID-19 patients were found in n = 24 (46.2%) of the publications analyzed.
Hydroxychloroquine is listed in the class of antimalarials with antiviral immunomodula-
tory effects [23,24]. An effect could be demonstrated with SARS-CoV in vitro and in vivo,
as well as with SARS-CoV-2 in vitro [23–25]. The safety profile of hydroxychloroquine is
known from decades of use under other indications (malaria, rheumatic diseases) [26].
Numerous clinical studies are currently being carried out to investigate the effectiveness
of hydroxychloroquine in COVID-19 [27]. Early results from clinical studies on hydrox-
ychloroquine in COVID-19 patients have contradictory conclusions [24]. N = 15 (28.9%)
publications mentioned a possible benefit of using remdesivir. Remdesivir is a nucleotide
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prodrug [23]. It is believed to inhibit the viral RNA-dependent RNA polymerase [28]. A de-
creased virus replication was detected for MERS-CoV (Middle East Respiratory Syndrome
Coronavirus) and the Ebola virus in animal experiments [29]. Shorter disease manifestation
has been reported among COVID-19 patients [28]. The treatment option with COVID-19
convalescent plasma was discussed in n = 8 (15.4%) of the analyzed publications. During
therapy with convalescent plasma, the plasma of recovered patients is transfused with
neutralizing antibodies to support the immune system [30]. Convalescent plasma has been
administered in the past for Ebola, SARS-CoV, MERS-CoV and influenza [31]. The use of
hydroxychloroquine, remdesivir or COVID-19 convalescent plasma in clinical studies has
had scientific value and advantages for study participants. Through their participation,
participants have the possibility to gain early access to treatments for which a therapeutic
effect is expected [32]. Randomization and the administration of placebo may hinder direct
benefits. This was often interpreted as a violation of the medical duty of beneficence.
Failure to provide timely access has been suggested as a reason for deviating from estab-
lished study designs during the pandemic [27]. Weaker evidence is accepted when this
allows us to offer life-saving therapy more quickly [12]. The use of drugs in off-label use
and compassionate use follows the principle of beneficence and does not primarily serve
scientific purposes, such as gaining knowledge about the effectiveness of drugs [27,33].
In the absence of proven effective measures, off-label use can be in line with the Declara-
tion of Helsinki, provided that patients received expert advice and informed consent was
obtained [34]. Close coordination with ethics committees is recommended [33].
3.2. Principle of Non-Maleficence
The principle of non-maleficence demands avoiding interventions with harmful con-
sequences [8]. This principle has implications on all five sub-themes. Recommendations
for the medication of hydroxychloroquine, remdesivir or COVID-19 convalescent plasma
to treat COVID-19 are mainly based on in vitro studies, results from animal experiments
and experience with other viral infections [23,31]. Positive results from in vitro research
or animal experiments cannot simply be transferred to humans [35]—even in emergency
situations, the major physiological differences between species need to be kept in mind.
The efficacy and safety of hydroxychloroquine for COVID-19 are not yet known. Cardiac
side effects, for example, have been described for its use under other indications (e.g.,
malaria, rheumatic diseases) [26]. Studies with hydroxychloroquine as a treatment option
were terminated due to emerging publications of studies that did not confirm any benefit
for treating COVID-19 [36]. Remdesivir was originally developed for hepatitis C and was
later considered for Ebola. However, remdesivir was not approved for the treatment of
hepatitis C or Ebola because the drug did not meet efficacy requirements [35]. The drug can
be described as a sleeping candidate [12]. The emergence of the new disease was a sudden
unexpected opportunity to finally give remdesivir a major use. The identification of new
uses for existing but abandoned drugs that previously did not generate profit is highly
advantageous for pharmaceutical companies. Therefore, the sub-theme non-medical influ-
ences on drug use, in particular economic interests, also played a role. In the United States,
remdesivir obtained emergency use authorization on 1 May 2020, based on preliminary
study results [37]. The actual benefit of remdesivir is so far an open question [15], as the
drug has not gone through the usual safety and efficacy review process that is normally
required before a drug is approved.
An emergency use authorization does not correspond to the regular approval process
of the drug authorities. The emergency use authorization is based on two clinical trials,
one of them was conducted by the manufacturer. The results of both studies were not
published at the time of the emergency use authorization [38]. A critical review process of
the data by independent researchers to complement the analysis of the regulatory authority
could not take place at the time of authorization. Such time-saving procedures come at
the cost of transparency. In this respect, there are parallels to oseltamivir. The drug was
used for treatment during the H1N1 influenza in 2009 outbreak based on limited research
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funded primarily by the drug company. Independent researchers who wanted to review
the data from clinical trials were not granted access. Years later, it was proven that the drug
did not have the effect promised by the manufacturer [39]. Earlier ethical guidelines on
pandemic planning place for such reasons a high value on “openness & transparency” [40].
Independent review allows to identify adverse reactions which manufacturers may not
fully disclose due to conflicts of interests. Furthermore, independent reviews allow to keep
expectations realistic, so that patients and populations at risk are less likely to develop
false hopes.
There are positive study results for the administration of convalescent plasma in
COVID-19. However, the study participants received antiviral drugs at the same time. It
could not be determined with certainty which effect was indeed triggered by COVID-19 con-
valescent plasma [30]. Most of the currently registered studies on COVID-19 convalescent
plasma are not double-blind randomized clinical studies [41]. The inclusion of participants
in studies that do not produce valid results is viewed as ethically unacceptable [42]. Pos-
sible risks of participating in the study are, among others, unknown serious side effects
or an ineffective treatment [32]. The often standardized exclusion criteria for potential
participants also comes with ethical conflicts. In particular, children, pregnant women,
breastfeeding women, the elderly or people with comorbidities are underrepresented in
medical research, which impedes adequate efficacy studies and the early identification
of negative side effects. An automatic exclusion of groups that are underrepresented in
medical research contradicts the Declaration of Helsinki, according to which these groups
should have adequate access to medical research [34]. COVID-19 research has failed to
include pregnant women, breastfeeding women, HIV-infected people, children and the
elderly [23,43,44]. These groups may suffer harm from such exclusionary policies when
results of studies performed on other groups cannot simply be translated to them [44–46].
Since hydroxychloroquine has already been used successfully for many years on pregnant
women and children, the exclusion of these patient groups in COVID-19 studies is viewed
as unjustified [44–46]. The exclusion of older COVID-19 patients has particularly harmful
consequences, as it leads to study results that are not representative for the patient group
with the highest COVID-19 mortality rates [43]. As a result, many patients have received
hydroxychloroquine, remdesivir and COVID-19 convalescent plasma in risky off-label or
compassionate use [24,47]. Even during emergencies, the use of drugs with poor evidence
for off-label use can violate the principle of non-maleficence [33]. Drugs such as remde-
sivir, which are used in compassionate use programs, have not been used in large patient
populations—serious side effects may therefore be unknown to date [47]. When using
drugs outside clinical studies in compassionate use, there is no systematic evaluation of
their efficacy [27].
3.3. Principle of Respect for Autonomy
Three of the five sub-themes relate to the principle of respect for autonomy: drug
research, treatment outside of clinical trials, and distribution of limited medicinal products
(including plasma). According to the principle of respect for autonomy, the patient’s
informed consent is required before any therapeutic measures [8]. A careful informative
process is a prerequisite for informed consent, which should not be waived or downplayed
during a pandemic [12]. The fact that a drug has not received regular approval must
be disclosed and patients need to be impartially informed about the possible risk and
benefits involved in the use of such drugs. In the case of patients capable of giving
consent, time constraints and the risk of confusing patients with the information provided
were cited as reasons for not seeking adequate informed consent during the COVID-19
pandemic [33,48]. Alternative consent procedures are in place for patients who are unable
to consent. The patient who is unable to give consent is represented by his or her legal
representative [23]. This procedure is in line with the Declaration of Helsinki [34]. A
general exclusion of vulnerable patient groups from clinical studies without justification
violates the self-determination of these patients. They should be given the opportunity
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to participate in COVID-19 studies following adequate informed consent [46]. It needs to
be noted, however, that in some cases, patients may fear disadvantages if they refuse to
participate in a clinical study when asked [24]. According to the Declaration of Helsinki,
potential test subjects should not suffer any disadvantage due to their refusal to participate
in a study [34]. Participation in a randomized, placebo-controlled study has an impact
on the patient’s self-determination, as he or she cannot decide for or against a particular
therapy. The study design does not allow the participant to actively choose to be treated
with a particular experimental drug instead of being given a placebo. According to the
Declaration of Helsinki, it is permissible to give a placebo if, as in the case of COVID-19, no
proven intervention option is available [34,49].
3.4. Principle of Justice
The principle of justice demands fair distribution and fair access to health services [8].
A connection to the principle of justice can be found on four sub-themes: drug research,
treatment outside of clinical trials, non-medical influences on drug use (e.g., political or
economic interests), and distribution of limited medicinal products (including plasma). In
n = 14 (26.9%) publications on hydroxychloroquine, n = 5 (9.6%) on remdesivir and n = 1
(1.9%) on COVID-19 convalescent plasma, the aspect of fairness in drug distribution was
discussed. The assumption that hydroxychloroquine could be effective in COVID-19 led
to supply shortages to treat patients for diseases for which the medicine was originally
developed and approved [24,50]. This leads to a situation which is difficult to assess with
the principle of justice. The interests of patients for which there is evidence that they will
benefit from the drug need to be weighed against the interests of those patients for whom
the drug is one of the few reasonable hopes for recovering under the state of emergency.
This situation becomes even more difficult to evaluate from an ethical perspective, as
there are no comparable drug alternatives for every approved indication [51]. Due to the
increased demand, there are fears that the price of hydroxychloroquine will rise, making
it inaccessible in low-income countries [26] and the uninsured. This involves the sub-
theme “non-medical influences”. Not only medical but also financial aspects are decisive
for the distribution and treatment with hydroxychloroquine. After the emergency use
authorization was granted in the United States, not enough remdesivir was available
for all eligible patients [37]. For both drugs, criteria had to be established for a fair
distribution [37,50].
Participation in clinical trials is seen as an option to obtain potentially effective drugs
on time [32]. Sometimes there are more interested participants for a clinical study than
those that can be included in them [52]. Refusing participants in the study on paternalistic
grounds contradicts the principle of respect for the patient’s autonomy. Although there is
awareness that randomized studies are indispensable for identifying potential COVID-19
drugs and their use, these are frequently used in off-label use [49]. With off-label use,
no scientifically reliable knowledge can be obtained about the drug used. As off-label
use only occurs on a case-by-case basis, results cannot be generalized. There is also a
risk of confirmation bias, as physicians may want to see a positive effect. Findings on
the efficacy and safety of unsystematic off-label use studies have therefore little scientific
value [33]. Despite the epistemic limitations of isolated experiences, a database that pools
these different experiences together using quantifiable parameters may have scientific
value on an aggregate level. One of the ethical recommendations after the experience
from the SARS outbreak of 2003 is to promote data sharing practices [53]. During public
health emergencies decisions often need to be taken with poor or no data. If clinicians
abide to a duty to share data with centralized institutions, this data can be curated and
be made publicly available to assist decision-making and thereby improve pandemic
response capabilities.
During the early phase of the pandemic, some countries did not have enough patients
to carry out clinical studies. If not enough patients are enrolled in clinical trials, it takes
longer for effective treatments to be discovered and used [54]. When these trials are
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randomized, only a subset of patients will receive this medicine. With a view to treating
patients equally, all patients are to be given the potentially effective drug [49]. Some
authorities have now banned the use of hydroxychloroquine outside of clinical trials for
COVID-19 [24]. The refusal to dispense hydroxychloroquine restricts self-determination in
favor of harm avoidance and fair distribution [51]. Different types of drug distribution and
selection criteria for inclusion in clinical trials to obtain drugs have been discussed. Possible
strategies are distributions according to the best individual risk-benefit ratio, by prioritizing
most health-endangered patients, or according to the “first come, first served” principle [37].
Researchers also see selection through a lottery system as an option [37,52]. When choosing
participants for clinical trials, a selection criteria aspiring to increase the scientific value
and the social benefit of the study can be ethically justified [52]. Making choices to mitigate
or minimize the impact of existing health disparities has been discussed [15].
4. Discussion
4.1. The Adoption of Ethical Principles and Guidelines
Our results reveal a variety of ethical drug use challenges during the early phase of
the COVID-19 pandemic. The availability of ethical guidelines from specialist societies
facilitates ethical decision-making for medical staff. However, these were not initially
available or needed adaptation to the new circumstances. The needed ethical guidelines
were developed under great time pressure in the early phase of the pandemic, requiring
further adjustments as the pandemic continued to reveal unforeseen social challenges,
the pathogen developed new mutations and new scientific discoveries were made. These
developments also lead to regular changes in recommended drug use. As there is still
no regularly approved drug for the treatment of COVID-19 and satisfactory solutions
for all ethical challenges have not been found, our findings from the early phase of the
pandemic continue to offer important insights. Even after more than a year of a pandemic,
it is necessary to continue to assess the ethical challenges that arose in the early phase of
the pandemic and develop clear ethical guidelines based on this experience to mitigate
current and future similar conflicts. For instance, we are currently witnessing similar
ethical conflicts with COVID-19 vaccines. The unknown risks and the distribution of the
limited number of vaccines available still raise major ethical questions. Our findings can
help to initiate measures to prevent or mitigate ethical challenges in the further course of
the pandemic. In addition, our findings are not only important for the ongoing pandemic
but also can play a major role to prepare for similar outbreaks in the future [55].
We observed that ethical issues in connection with the use of drugs in clinical studies
arise primarily in relation to informed consent and the design of the study. Weakening
informed consent requirements contradicts the principle of respect for the patient’s auton-
omy but could be argued for by appealing to beneficence [8,33]. Demanding randomized
trials during a pandemic is controversial [27,49,54]. Proponents claim that health crises are
no excuse for lowering scientific standards [27]. Opponents defend the position that it is
more important to treat patients in time based on current knowledge than to generate new
knowledge following complex studies [54]. When it comes to questions of drug distribu-
tion, all four ethical principles collide [51]. A full consideration of the complex interactions
between the ethical principles harbors ethical dilemmas for the treating physicians [24,49].
In our analysis of the experimental drug use during the early stage of the pandemic,
the use of hydroxychloroquine was associated with the largest number of ethical conflicts,
followed by remdesivir. COVID-19 convalescent plasma played a minor role in relation
to hydroxychloroquine and remdesivir. The five sub-themes identified in the thematic
analysis can be grouped in four discussion points by referring to the four ethical principles:
Unknown risks and benefits ratios, informed consent, study design and fair distribution of
drugs (Table 1).
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Table 1. Determining ethical arguments within the five identified sub-themes.
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4.2. The Adoption and Development of Ethical Principles and Guidelines in Germany
To illustrate the significance of these findings, we use the German regulatory system as
a case study to discuss the extent to which the ethical controversies and recommendations
identified in international publications are reflected in practice. We decided to focus on
Germany for three reasons. First, all three analyzed medicinal products were among the
main candidates for experimental treatment in the early phase of pandemic in Germany.
According to the EU registry for clinical studies (as of 12 April 2021), all three drugs were
used at some point during the early phase of the pandemic in clinical trials for COVID-19
in Germany. In addition, they were also used outside of clinical trials. None of the three
drugs went through a regular drug approval process for COVID-19 in Germany [20,56].
Second, from early on, ethics groups were involved in providing ethical guidance on
using drugs for experimental therapies. As different groups and institutions worked in
parallel and in cooperation, we are able to refer to multiple position papers to illustrate how
ethical guidelines became incorporated in public health policies and recommendations.
Third, the work between ethics groups and public institutions was generally perceived
as constructive and related publications were well received. Uniform guidelines were
available early on nationwide, which was considered as desirable by other states. In
Germany, the close collaboration between professional societies and the publishing of
common guidelines prevented polarization. The Public Health Competence Network on
COVID-19, for example, is an ad hoc association of more than 25 scientific specialist societies
in the field of public health that bundle their specialist knowledge. Such associations could
contribute to the rapid development of guidelines that enjoyed high acceptance and helped
to support the stakeholders involved. Countries without standardized guidelines often
had contradictory recommendations at regional and local levels. In some cases, medical
professionals were not sure which guidelines to follow. Experts therefore called for uniform
national ethical guidelines [57], such as those that were in use in Germany.
4.2.1. Unknown Risks and Benefits Ratios
Research results on hydroxychloroquine, remdesivir and COVID-19 convalescent
plasma hold out the prospect of a potential benefit for people with COVID-19. During
the early pandemic, the use of the three drugs on people with COVID-19 was compatible
with the principle of beneficence, as COVID-19 was associated with a high mortality and
hospitals were running out of capacity. At the same time, general clinical practice dictates
cautiousness when convincing results from large clinical studies are missing. There is the
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risk that patients suffer greater harm than benefits when administered any of the three
drugs, violating the principle of non-maleficence.
Remdesivir received conditional marketing authorization for the European Union
member states on 3 July 2020. Before approval, it was available for compassionate use in
Germany [20]. This formal change brought economic advantages for the pharmaceutical
company, since drugs for use by patients in compassionate use in Germany have to be
made available free of charge by the pharmaceutical manufacturer [10]. This is no longer
the case with a conditional marketing authorization. The five-day treatment costs about
2.000 euros (2.340 dollars) per patient [58]. Even if recent data for remdesivir could not
confirm a positive benefit-risk ratio, the company benefited financially during the period
of conditional marketing authorization, which is limited to one year [18]. In the case of
hydroxychloroquine, the influence of financial interests cannot be completely ignored
either. Hydroxychloroquine is a relatively cheap drug at under 20 euros for 30 tablets
in Germany. But scientists have already expressed concerns that the widespread pro-
motion of hydroxychloroquine could encourage fraud and counterfeiting of drugs [26].
This can lead to additional risks. According to information from the Federal Institute
for Drugs and Medical Devices (BfArM), COVID-19 patients in Germany can currently
(April 2021) receive hydroxychloroquine in off-label use [20]. The use of COVID-19 con-
valescent plasma is permitted in Germany as a non-approved drug, outside of clinical
studies, to carry out an individual healing attempt (Necessity as a justification, Section
34 German Criminal Code [22]). The Paul Ehrlich Institute published recommendations
for its extraction and production [56]. Uncertainties regarding the potential benefits and
harms of hydroxychloroquine, remdesivir and COVID-19 convalescent plasma are also
recognized by German health authorities [20,56]. According to a survey by German ethics
commissions, a risk-benefit assessment in intervention studies is problematic given the
current state of knowledge [7].
4.2.2. Informed Consent
According to Beauchamp and Childress, informed consent is the cornerstone of the
principle of respect for autonomy and is therefore one of the most important processes in
medical ethics [8]. The Declaration of Helsinki states that each patient must be adequately
informed about the expected benefits and potential risks [34]. The provision of the nec-
essary information to seek informed consent is difficult when risks and benefits are still
not sufficiently known [32,48]. It must be made clear in the information process that the
communicated risks and benefits involve uncertainties. Ideally, patients should be offered
updated information as soon as new relevant scientific findings emerge to reassess their
consent [59]. We identified ethical issues related to informed consent in the sub-themes
“drug research” and “treatment outside of clinical trials” (Table 1). In Germany, ethical
challenges in relation to informed consent concentrate on uncertainties with regard to
alternative options for consent, the classification of patients as incapable of consenting
and isolation measures [7]. In contrast to other scientists, the Working Group of the Medi-
cal Ethics Commissions in Germany does not consider the waiving of informed consent
requirements for patients with an acute COVID-19 infection [4,33]. The Working Group
supports the statements on informed consent of the “Guidance on the Management of
Clinical Trials during the COVID-19 (Coronavirus) pandemic”, prepared under the coor-
dination of the European Medicines Agency [4,60]. This guidance refers as an alternative
to written consent by the trial participant, for example, by recognizing oral consent in the
presence of an impartial witness or consent by a legal representative to minimize the spread
of the disease [60]. The first version of this EU guidance was published on 20 March 2020
and thus offers the first ethical advice specifically tailored to COVID-19 at a very early
stage of the pandemic.
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4.2.3. Study Design
Germany was involved in studies on the use of hydroxychloroquine during the
early phase of the pandemic. Currently, there is no reference to ongoing studies on
hydroxychloroquine in COVID-19 with German participation in the EU Clinical Trials
Register (as of 12 April 2021). Stopping a clinical trial with disappointing interim results
can avoid harming patients and is in line with the principle of non-maleficence. Germany
is still conducting clinical studies on remdesivir and COVID-19 convalescent plasma. There
continues to be an expectation among scientists that these treatment options will deliver
promising results. The use of remdesivir and COVID-19 convalescent plasma can therefore
be in accordance with the principle of beneficence. The Working Group of the Medical
Ethics Commissions in Germany points out that study results from COVID-19 research are
needed quickly, but only qualitatively high-quality studies, such as interventional studies,
can be rated positively as comparable controlled studies [4]. In this respect, German ethics
commissions comply with the demand of not allowing lower scientific standards in research
during the pandemic [27]. Germany is involved in the global drug study SOLIDARITY
with a very heterogeneous study population. This study does not automatically exclude
patient groups that are often neglected in research [12]. The automatic exclusion of specific
groups contradicts the principle of respect for autonomy. However, in WHO registered
studies within the “COVID-19 and pregnancy” category, no study was found whose
sponsor is in Germany [45]. Since patients are better monitored in clinical trials than,
for example, in compassionate use, participation in the study would be preferable for
vulnerable groups and individuals in accordance with the principle of non-maleficence [10].
Ethics committees in Germany are also dealing with inclusion and exclusion criteria. For
example, issues arise in the allocation of patients to studies when there are only a very
limited number of infected people and they can be included in multiple studies at the
same time [7]. Internationally, a differentiated picture emerges: there is sometimes an
oversupply of studies, and sometimes an oversupply of potential study participants [27,52].
This situation has of course drastically changed since October 2020.
4.2.4. Fair Distribution of Medicines
Although a shortfall of hydroxychloroquine is often mentioned in the literature, it
does not contain any concrete figures of a supply bottleneck. It is reported that patients
with lupus erythematosus were unable to redeem their prescriptions [51]. The actual extent
of the shortfall is not specified. The situation in Germany seems to be comparable to the
one depicted in international reports. In a survey at the end of April 2020 among n = 66
rheumatologists in Germany, 65.9% of those questioned stated that there was a shortage of
the drugs they had prescribed. Hydroxychloroquine and chloroquine (n = 30) were men-
tioned most frequently [61]. The list of reported delivery bottlenecks of the BfArM did not
reveal a delivery shortfall for hydroxychloroquine at any time. On 3 April 2020, the higher
federal authority published a notice intended to ensure the supply of hydroxychloroquine
for chronically ill patients with the approved indications [20]. A request to the BfArM for
specific figures did not lead to any result. The action of the BfArM can be seen as an action
in favor of patients who have already received hydroxychloroquine before the pandemic.
It serves the principle of beneficence for these patients as they already have built their
lives under the reasonable expectation that they can count with continuous access to the
drug. Even if no serious ethical dilemmas due to drug shortages have been reported in
Germany so far, this issue should continuously be reevaluated. If resources are scarce,
the ethical prerequisites for permissible treatment measures set out in the guidelines on
intensive care therapy would not be met. Medical indication and the patient’s will are
not the only decisive factors [62]. With a view to the principle of justice, the interests of
patients with prior conditions need to be taken in consideration when assessing issues of
justice and should not be overseen during emergencies. Future pandemic planning needs
to consider the difficult ethical question on how to proceed if scarce medicines used by
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people with prior conditions would actually save many more people when applied for
newly identified uses.
4.2.5. Institutionalization of Ethical Norms and Implications for Future Practice
During the pandemic, decisions often have to be made under time pressure. There is a
constant temptation to override standard protocols to save time. However, in the analyzed
publications, there is no call for limiting the involvement of ethics committees to save time.
The crucial role of ethics committees during the pandemic in the assessment of ethical
issues on drug use in clinical studies has been pointed out several times [30,32,33]. The
regular participation of ethics committees in clinical studies in Germany, on the other hand,
was restricted by Section 8 (2) of the “Medical Needs Supply Guarantee Ordinance” [63].
In contrast to the legal situation before the pandemic, a lead ethics commission evaluates
multicenter clinical trials on COVID-19 in Germany, which are carried out in more than one
trial center without further consultation with the local ethics committees. This legal change,
with further ordinances and notices in the pharmaceutical sector, reduces regulatory
hurdles during the pandemic. At first sight, the removal of regulatory hurdles to accelerate
processes appears as beneficial, but it may lead to a failure to address the specific needs
of those involved in drug use. There is consensus in Germany and at an international
level that additional recommendations, guidelines and regulations for off-label use in crisis
situations, drug distribution and clinical trials are useful [7,37,48,51,64]. The first concrete
measures to develop appropriate recommendations have already been taken in Germany.
As part of the PRECOPE project, practice-oriented recommendations for dealing with the
most relevant ethical challenges in biomedical research using human subjects are being
developed [7].
Comparable projects are missing for ethical questions regarding off-label use in crisis
situations and fair distribution of drugs. Although there is an expert group for off-label
use at the BfArM, it does not deal with ethical issues related to this [65]. A centralized
registration of off-label use and its effects and side effects can facilitate future decision-
making, especially if it includes uses without clinical trials, on the basis of small trials,
or trials with study designs other than randomized controlled trials. Since off-label use
not only plays a role in emergency situations but also in regular practice, especially in
pediatrics and oncology, ethical recommendations should be drawn up for off-label use
in and outside of emergency. To make sure physicians share crucial data even under
time pressure, ethicist need to provide strong arguments on why data sharing is ethically
demanded by ideas of reciprocity and solidarity [53].
In line with the principle of justice, considerations should be made for the equitable
distribution of medicines. Professional societies are currently preparing a recommendation
for the appropriate use of remdesivir. This should lead to guaranteed access for patients
who could benefit from remdesivir [66]. In addition to questions of proper use, we face
ethical challenges when there are insufficient drugs available for all eligible patients.
Making recommendations for the distribution of limited medical supplies poses many
ethical challenges [2].
4.3. Summary of General Recommendations
Future recommendations need to be drawn up at an early stage and made publicly
available. They should not be drafted under time pressure and already discuss a wide
range of possible scenarios. We have listed our main findings from our ethical analysis
in Table 2.
Int. J. Environ. Res. Public Health 2021, 18, 5685 13 of 16
Table 2. Recommendations based on the experience during the early pandemic.
Ethical Principle Recommendations
Beneficence
- Maintain openness to discuss experimental treatment options
with patients from all population groups who are in urgent need
Non-maleficence
- Expand inclusion for clinical studies criteria to avoid missing
potentially negative effects on excluded groups (e.g., pregnant
women, elderly)
Respect for autonomy
- Avoid paternalistic attitudes when excluding systematically
participants from higher risks groups
Justice
- Establish guidelines to secure sufficient access to repurposed
drugs for patients with prior conditions
- Establish protocols to authorize the recording of patient reactions
to drugs in off-label use
4.4. Limitations
Our analysis concentrates on the first ten months of the pandemic to identify the main
ethical arguments on experimental medicines that acted as guiding principles during the
early phase of the COVID-19 outbreak. Extensive ongoing research activity on COVID-
19 comes with a rapid change in the state of knowledge on pharmaceutical treatment
options. For example, a year after the start of the pandemic, hydroxychloroquine no longer
plays a major role as a treatment option for COVID-19 [67]. In contrast, other drugs such
as dexamethasone, the antibodies bamlanivimab and RegnCoV-2 or the asthma spray
budenoside are gaining attention in research and medical practice [20,68,69]. The use of
many of these new drugs follows the same ethical reasoning behind our analyzed cases
on experimental drug use. Therefore, while the drugs being used experimentally have
changed, the ethical challenges identified in our analysis are still similar even after more
than a year of COVID-19 pandemic. This ethical analysis is widely transferable to other
potentially effective medications during public health emergencies and can assist ethical
decision-making in future pandemic planning. At the time of writing (April 2021), there
are no medicines that have shown fully supportive evidence in a phase 3 trial and have
gone through a regular authorization procedure.
A shortcoming of having relied on a principle-based approach, is that such an ethical
approach is primarily forward-looking. This approach has the benefit of providing clear
guidelines with which affected groups and policymakers can familiarize themselves. While
the principle of justice allows us to identify ethical issues that need to be redressed, it does
not emphasize the importance of continuously carrying out an ethical assessment when
encountering new information to revise guidelines. Future work on experimental drug uses
needs to explore the potential of ethical approaches that have a solid backward-looking
component, who place a high value on “reasonableness” and “responsiveness” [40] to
continuously revise guidelines when encountering new problems and opportunities.
5. Conclusions
This analysis of the ethical challenges in relation to drug use during the early COVID-
19 pandemic shows that drug safety and distribution issues affect all four ethical principles,
leading to frequent conflicts between them. Among the main ethical challenges we have
identified, we discussed the effect of unknown risks and benefits, informed consent, study
design limitations and the fair distribution of medicines. Drug safety issues are equally
challenging for all three hydroxychloroquine, remdesivir and COVID-19 convalescent
plasma. In contrast to the international discussion, the fair distribution of medicines seems
to play a subordinate role in Germany. Only hydroxychloroquine briefly came into the
focus of ethical discussions. Our results confirm some of the ethical challenges addressed
in the PRECOPE project. In relation to the ethical aspects of drug use, they go beyond
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this, as they also include their experimental use outside of clinical studies. Knowledge
of these challenges offers the opportunity to take appropriate action. The drafting and
implementation of new ethical recommendations can help to minimize ethical challenges
and thereby lead to positive effects on future clinical research, the administration of drugs
in off-label use and drug distribution in and outside of times of emergency.
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